AOD9604

AOD9604

AOD9604 is a synthetic peptide fragment derived from human growth hormone (hGH), originally developed and studied as a potential weight-loss/fat-reduction compound.

What it is

AOD9604 corresponds to the C-terminal fragment (amino acids 176-191) of the human growth hormone molecule — specifically the region believed to be responsible for GH’s fat-metabolizing effects, without the growth-promoting (insulin-resistance-inducing) effects of full-length GH.

How it’s thought to work

• Full-length HGH stimulates fat breakdown (lipolysis) but also has significant side effects, including effects on blood sugar/insulin and tissue growth
• AOD9604 was designed to isolate just the lipolytic (fat-burning) fragment of the GH molecule, theoretically retaining the fat-loss benefit while avoiding GH’s growth-related side effects
• It’s proposed to work by mimicking GH’s action on fat cells — stimulating breakdown of stored fat and inhibiting the formation of new fat (lipogenesis), without raising IGF-1 or blood glucose levels the way full GH does

Research history

• Developed by Professor Frank Ng and colleagues at Monash University (Australia), later licensed to a company called Metabolic Pharmaceuticals
• Underwent Phase I and Phase II human clinical trials in the early-to-mid 2000s for obesity
• Despite initial promise, Phase IIb trials failed to show significant weight-loss efficacy compared to placebo, and development for weight loss was discontinued
• It was never approved by the FDA, TGA (Australia), or any other regulatory body for human use

Current status

• Not an approved drug anywhere for any indication
• In some jurisdictions (e.g., Australia), it’s technically classified in ways that have caused regulatory confusion — it doesn’t meet the legal definition of HGH and so fell into a gray area for a period, but this doesn’t mean it’s approved or legal to sell as a supplement in most places
• Commonly sold in the unregulated “research chemical” and peptide/bodybuilding supplement marketplace, usually labeled “not for human consumption”
• No verified human safety or efficacy data supports its use as a weight-loss product

As fundamentally: the trials that actually tested whether it works for weight loss failed to show it was better than placebo — a detail often left out of marketing claims. Happy to go deeper on the trial data or the GH fragment mechanism itself.